Celularity Inc. Class A Common Stock (CELU)
NASDAQ
Closed
Oct 23, 2026
Day's Range
0.911052 wk Range
0.5600Overview - CELU - Celularity Inc. Class A Common Stock
Key Statistics
Valuation
Enterprise Value
118.33M
P/E (Trailing)
2.27
P/E (Forward)
-2.73
PEG Ratio
-2.73
Price / Sales (TTM)
2.66
EV / EBITDA
-2.19
Profitability
Gross Margin
-79.67%
Profit Margin
24.39%
Operating Margin
-263.46%
Return on Assets
-32.32%
Return on Equity
241.18%
Ownership
Shares Outstanding
28.83M
Float
22.37M
Short % of Shares Outstanding
3.85%
Held by Insiders
33.16%
Held by Institutions
11.42%
Price stats
Beta
0.77
50-Day Avg
1.20
200-Day Avg
1.10
Dividends
Payout Ratio
0.00%
Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - CELU - Celularity Inc. Class A Common Stock
Peers - CELU - Celularity Inc. Class A Common Stock
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- CELUNASDAQCelularity Inc.50.62MMarket Cap-30.77%52-week change2.28P/E (Trailing)24.39%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - CELU - Celularity Inc. Class A Common Stock
About
Celularity Inc. Class A Common Stock represents the equity of Celularity Inc., a cellular and regenerative medicine company focused on developing placental-derived therapies and biomaterial products. Celularity’s current business centers on three operating segments: Cell Therapy, Degenerative Disease, and BioBanking.…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
